Neurona raises $102m to advance cell therapy for drug-resistant epilepsy
Neurona will kick start a Phase III trial in H2 2025 investigating NRTX-1001 in patients with a type of drug-resistant epilepsy.
Neurology
AD/PD 2025: DHTs can detect disease progression in patients with early Parkinson’s
GSK and UK researchers plan to study Shingrix and dementia risk reduction link
Tempero secures $70m to advance addiction treatment candidate
Augustine secures $85m to advance Charcot-Marie-Tooth candidate
SmartCella gains rights to advance cell therapy research for Parkinson’s
Supernus wins FDA approval for Parkinson’s pump on fourth try
Eisai and Biogen’s subcutaneous Leqembi set for FDA review
